ArticleBMC gastroenterology2026
Feasibility, safety and accuracy of a novel robotic navigation system for cone-beam CT-guided and TACE-assisted radiofrequency ablation of hepatocellular carcinoma, a preliminary study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the technical feasibility, targeting accuracy and short-term safety of a novel integrated system of the robot-navigated, cone-beam CT (CBCT)-guided and transarterial chemoembolization (TACE)-assisted radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) in high-risk locations. MATERIALS AND
methodsThis retrospective, single-center study enrolled 11 participants with HCC lesions in high-risk locations. All participants underwent TACE followed by RFA navigated by a novel robotic system. Trajectory planning was based on respiratory-gated CBCT images and the subsequent needle insertion was guided by real-time fluoroscopy. The evaluated outcomes included the first placement accuracy, the adequate placement accuracy, targeting time, repositioning times, radiation exposure dose, complications and the 1-month complete ablation rate.
resultsThe cohort included 10 males and 1 female. Technical success was achieved in 100% (11/11) of cases. The median tumor diameter was 16.20 mm and the mean tumor depth was 79.37 mm. Seven tumors were located in the subdiaphragmatic position, three tumors were situated adjacent to major vascular structures and one tumor was located adjacent to extrahepatic organs. The median Euclidean error and angle error of the first placement were 6.2 mm and 3.0 degrees, respectively. The median Euclidean error and angle error of the adequate placement was 2.2 mm and 1.3 degrees. The median targeting time was 6.70 min (range, 1.55-29.52 min) and the median number of repositioning adjustments was 2. The mean cumulative air kerma was 216.34 mGy. The 1-month complete ablation rate was 81.8% (9/11) following adjunctive ablation in 2 patients. No major complications were reported.
conclusionThe integrated platform of robotic-navigated, real-time CBCT-guided, and TACE-assisted RFA is technically feasible and demonstrates short-term safety. In this cohort, it achieves preliminary targeting accuracy for the ablation of HCC in high-risk locations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.